Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from human chondrosarcoma cells resistance to ET-743 and PM00104

ABSTRACT: ET-743 (trabectedin, Yondelis®) and PM00104 (Zalypsis®) are marine derived compounds that have antitumor activity. ET-743 and PM00104 exposure over sustained periods of treatment will result in the development of drug resistance, but the mechanisms which lead to resistance are not yet understood. Human chondrosarcoma cell lines resistant to ET-743 (CS-1/ER) or PM00104 (CS-1/PR) were established in this study. The CS-1/ER and CS-1/PR exhibited cross resistance to cisplatin and methotrexate but not to doxorubicin. Human Affymetrix Gene Chip arrays were used to examine relative gene expression in these cell lines.

ORGANISM(S): Homo sapiens

PROVIDER: GSE16748 | GEO | 2009/06/24

SECONDARY ACCESSION(S): PRJNA117449

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of human chondrosarcoma cells resistant to ET-743 and PM00104

Project description:ET-743 (trabectedin, YondelisÂ®) and PM00104 (ZalypsisÂ®) are marine derived compounds that have antitumor activity. ET-743 and PM00104 exposure over sustained periods of treatment will result in the development of drug resistance, but the mechanisms which lead to resistance are not yet understood. Human chondrosarcoma cell lines resistant to ET-743 (CS-1/ER) or PM00104 (CS-1/PR) were established in this study. The CS-1/ER and CS-1/PR exhibited cross resistance to cisplatin and methotrexate but not to doxorubicin. Human Affymetrix Gene Chip arrays were used to examine relative gene expression in these cell lines. Experiment Overall Design: Three samples CS-1/ER, CS-1/PR and CS-1 were compared.

2009-07-05 | E-GEOD-16748 | biostudies-arrayexpress

Gene and microRNA modulation upon ET-743 treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line [miRNA expression]

Project description:Transcriptional profiling and microRNA profiling of paired PDX and derived cell line MT-CHC01 upon ET-743 treatement Intrahepatic cholangiocarcinoma (ICC) is an aggressive and lethal malignancy with limited therapeutic options. ET-743 has a high antitumor activity in preclinical models of biliary tract carcinoma (BTC), being a promising alternative treatment. Here, we studied the effect of ET-743 at transcriptomic level on an ICC patient derived xenograft (PDX) and on the derived cell line, MT-CHC01. Further, putative targets of ET-743 were explored in the in vitro model. In vitro, ET-743 inhibited genes involved in protein modification, neurogenesis, migration, and motility; it induced the expression of genes involved in keratinization, tissues development, and apoptotic processes. In the PDX model, ET-743 affected ECM-receptor interaction, focal adhesion, complement and coagulation cascades, Hedgehog, MAPK, EGFR signaling via PIP3 pathway, and apoptosis. In MT-CHC01, 24 microRNAs were deregulated upon drug treatment. Only 5 microRNAs were perturbed by ET-743 in PDX; 2 up and 3 down-regulated. Among down- regulated genes, we selected SYK and LGALS1; their silencing caused a significantly reduction of migration, but did not affect proliferation in MT-CHC01 and WITT cells. In conclusion, we described that ET-743 affected genes and microRNAs involved in tumor progression and metastatic processes, reflecting data previously obtained at macroscopically level; in particular, we identified SYK and LGALS1 as new putative targets of ET-743.

2017-06-10 | GSE84938 | GEO

Gene and microRNA modulation upon ET-743 treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line [gene expression]

2017-06-10 | GSE84918 | GEO

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models

Project description:Transcriptional profiling of EGI-1 xenografts and patient derived xenografts CHC001 PDX after treatment with ET-743

2017-02-09 | GSE63043 | GEO

Zea mays cultivar:RSQ-743

Project description:Zea mays RSQ-743 Transcriptome

| PRJNA493332 | ENA

Acinetobacter sp. WC-743

Project description:Acinetobacter sp. WC-743 Genome sequencing and assembly

| PRJNA53455 | ENA

Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma either responsive or resistant to trabectedin treatment.

Project description:Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma with either FUS-CHOP type I, named as ML017, or FUS-CHOP type III, named as ML006. Both ML017 and ML006 are responsive to trabectedin treatment, while model ML017/ET has aquired resistance to the drug. Samples are either under untreated conditions, or treated either with trabectedin or pioglitazone or both.

2020-01-10 | E-MTAB-8632 | biostudies-arrayexpress

Vibrio vulnificus strain:99-743

Project description:Vibrio vulnificus strain:99-743 Genome sequencing and assembly

| PRJNA299128 | ENA

Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma

Project description:RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ecteinascidin 743 in treating patients who have advanced soft tissue sarcoma.

| 2003402 | ecrin-mdr-crc

Homo sapiens

Project description:Expression data from human chondrosarcoma cells resistance to ET-743 and PM00104

| PRJNA117449 | ENA